Edition:
United Kingdom

IRIDEX Corp (IRIX.OQ)

IRIX.OQ on NASDAQ Stock Exchange Global Market

7.42USD
22 Feb 2018
Change (% chg)

$0.36 (+5.10%)
Prev Close
$7.06
Open
$7.12
Day's High
$7.42
Day's Low
$7.12
Volume
1,723
Avg. Vol
6,765
52-wk High
$16.09
52-wk Low
$6.67

Latest Key Developments (Source: Significant Developments)

Societe Quantel Issues Response To Iridex Press Release​
Wednesday, 10 Jan 2018 

Jan 10 (Reuters) - Societe Quantel Sa ::‍QUANTEL ISSUES RESPONSE TO IRIDEX PRESS RELEASE​.‍WE DO NOT ANTICIPATE ANY DISRUPTION TO OUR ONGOING COMMERCIAL PROGRESS​.SAYS BELIEVES ‍IRIDEX'S ACTION IS WITHOUT MERIT​.‍QUANTEL INTENDS TO VIGOROUSLY DEFEND ITSELF AGAINST CLAIMS​.  Full Article

Iridex Corp ‍Filed Lawsuit Against Quantel Medical S.A
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Iridex Corp ::IRIDEX CORP - ‍FILED LAWSUIT AGAINST QUANTEL MEDICAL S.A., QUANTEL USA, QUANTEL, S.A. IN U.S. DISTRICT COURT FOR NORTHERN DISTRICT OF CALIFORNIA​.  Full Article

Iridex Corp reports qtrly loss per share $0.27‍​
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Iridex Corp :Iridex announces 2017 third quarter financial results.Q3 revenue rose 11 percent to $10.9 million.Iridex Corp - ‍Iridex reiterates its previously provided estimate for revenue, and g6 system and g6 probe shipments for full year 2017​.Iridex Corp - qtrly loss per share $0.27‍​.  Full Article

Iridex Q3 preliminary revenues of approximately $9.6 to $9.7 mln
Tuesday, 11 Oct 2016 

Iridex Corp : Iridex announces preliminary revenues for 2016 third quarter . Preliminary revenues of approximately $9.6 to $9.7 million for q3 ended october 1, 2016 . Iridex - while demand for Cyclo G6 laser platform for glaucoma remained strong, revenues of certain retina products were below expectations ."demand for company's new flagship Cyclo G6 laser platform for glaucoma remained strong".  Full Article

Iridex sees Q3 revenue $11 million to $11.3 million
Thursday, 4 Aug 2016 

Iridex Corp : Q2 loss per share $0.03 . Q2 revenue rose 32 percent to $11.9 million . Month results . Sees Q3 2016 revenue $11 million to $11.3 million . Company continues to expect revenue growth for full year 2016 to be in low double-digits .Expect higher revenue in q4 relative to q3 due to typical seasonality.  Full Article

BRIEF-Blueline Capital Partners LP Reports 8.5 pct Passive Stake In Iridex Corp As Of Dec. 31, 2017

* BLUELINE CAPITAL PARTNERS LP REPORTS 8.5 PERCENT PASSIVE STAKE IN IRIDEX CORP AS OF DECEMBER 31, 2017 - SEC FILING‍​ Source text - (http://bit.ly/2F0uMll) Further company coverage: